DCSIMG
Insomnia Epidemiology & Prevalence
Sanofi Logo
Text Size – + |   FAQs  |  Site Map  |  Contact Us  |   Consumer Site
For U.S. Healthcare Professionals Only
AMBIEN CR (Zolpidem Tartrate Extended Release) Sleep Aid

FOR HEALTHCARE PROFESSIONALS

Give your patients
a good night's sleep...
FOR LESS

Share the AMBIEN CR Offer Card with your patients for up to $20* off each of their next 12 prescriptions.

Learn More
Skip Navigation Links

Epidemiology & Prevalence of Insomnia

Email to Your Friend Send to a Friend   Print Print Page
Many insomnia sufferers are undiagnosed and untreated 1,2

A 2008 study of health and wellness reveals some surprising facts about the epidemiology and prevalence of insomnia and sleep difficulties.1

In this extensive study of more than 35,000 U.S. adults, 37% reported sleep difficulties within the previous 12 months. Out of this group, only 53% spoke to their doctors about their sleep issues, with 83% receiving a diagnosis of insomnia or sleep difficulties.1

Among diagnosed sufferers1:

  • 41% treat with a prescription
  • 18% treat with an OTC medication only
  • 41% are untreated

Among non-diagnosed sufferers:

  • 30% take an OTC medication
  • 70% are untreated

Among those who did not discuss their sleep difficulties with their doctors:

  • 21% take an OTC medication
  • 79% are untreated

Next: Co-morbidity of Insomnia

pagedivide

* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions), depending on your out-of-pocket costs. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, or any private payor in the state of Massachusetts and where prohibited by law.

AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

IMPORTANT SAFETY INFORMATION

In elderly or debilitated patients, or patients with hepatic insufficiency, the recommended dose is 6.25 mg and patients should be closely monitored. Due to its rapid onset of action, patients should take AMBIEN CR right before going to bed and when ready for sleep. Patients should not take AMBIEN CR unless they are prepared to get a full night’s sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN CR or any other sleep medication. Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN CR and in rare cases may be fatal. Patients who develop angioedema should not be rechallenged. In primarily depressed patients, worsening of depression, including risk of suicidal thoughts or actions, including completed suicides, have been reported. The most commonly observed adverse effects in controlled clinical trials were headache, somnolence, and dizziness. Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN CR or any other hypnotic. AMBIEN CR is a Schedule IV controlled substance.

Please refer to the full prescribing information.